Kuwait Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Kuwait Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Kuwait Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: The gradual economic recovery will support the government's plans within the healthcare sector; however, political instability poses the greatest risk to our outlook. Kuwait's political backdrop is complicated by labour and population imbalances, as well as a parliament which has consistently blocked the government's reform efforts. While these healthcare reforms are still likely to be implemented, changes to the election law reform mean they are vulnerable to lengthy delays as political tensions continue to elevate.

Headline Expenditure Projections

  • Pharmaceuticals: From KWD300mn (USD1.0bn) in 2015 to KWD312mn (USD1.02bn) in 2016; +4.1% in local currency terms and +2.8% in US dollar terms. Forecast in line with Q 4 1 6 .

  • Healthcare: From KWD1.61bn (USD5.33bn) in 2015 to KWD1.74bn (USD5.66bn) in 2016; +8.1% in local currency terms and +6.1% in US dollar terms. Forecast in line with Q4 1 6 .

Headline Pharmaceuticals & Healthcare Forecasts (Kuwait 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
Source: National Sources/BMI
Pharmaceutical sales, USDbn 1.006 0.997 1.018 1.047 1.089 1.139 1.193
Pharmaceutical sales, % of GDP 0.62 0.91 0.96 0.88 0.86 0.86 0.83
Pharmaceutical sales, % of health expenditure 19.4 18.7 18.0 17.5 17.1 16.8 16.6
Health spending, USDbn 5.197 5.333 5.656 5.991 6.371 6.776 7.186

Risk/Reward Index

In our Q117 Pharmaceutical Risk/Reward Index Kuwait scores 53.3 out of 100. Decreasing from a Q416 score of 54.5, the country now ranks behind the UAE, Saudi Arabia and Israel, as the fourth most attractive market in the region. The burden of diabetes will continue to expand in the region as the population ages and adopts increasingly sedentary lifestyles. Increasing insurance coverage and rising income levels will lead to greater spending on diabetes, and commercial opportunities will be sought by multinational pharmaceutical companies, health insurers and providers.

Latest Updates

  • In September 2016, health minister Al Obaidi launched healthcare for retirees with the distribution 117,000 cards for eligible citizens across 45 government offices at a total cost of KWD82mn. The service is said to be part of an ongoing effort to increase cooperation between the government and the National Assembly.

  • In September 2016, a Kuwait medical delegation visited Qatar's Haj mission, Makkah, to discuss the establishment a Gulf medical entity under the jurisdiction of Gulf Haj missions. Proposals will be presented to officials at the meeting of GCC Health Ministers as part of efforts to offer better medical services for Gulf pilgrims.

BMI Economic View

We expect the Central Bank of Kuwait (CBK) to follow the US Federal Reserve (Fed) when it hikes its policy rate by 25 basis points in 2017. This will be a repeat of 2015, when the CBK raised its benchmark rate less than 24 hours after the US institution had done so. As a result, we forecast Kuwait's policy rate to stand at 2.50% by the end of 2017, compared to 2.25% at end-2016.

BMI Political View

Kuwait's National Assembly will continue to block fiscal consolidation reforms that impact Kuwaiti citizens, and divert austerity towards expatriates. As a result, the country will remain a reform laggard in the GCC. This will pose little risk to Kuwait's stability, given the colossal financial buffers at its disposal.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Kuwait 2014-2020)
7
SWOT
9
Industry Forecast
12
Pharmaceutical Market Forecast
12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Kuwait 2012-2020)
13
Healthcare Market Forecast
15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Kuwait 2012-2020)
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Kuwait 2012-2020)
17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Kuwait 2012-2020)
17
Prescription Drug Market Forecast
18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Kuwait 2012-2020)
19
Patented Drug Market Forecast
20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Kuwait 2012-2020)
22
Generic Medicines Market Forecast
23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Kuwait 2012-2020)
24
OTC Medicine Market Forecast
25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Kuwait 2012-2020)
26
Pharmaceutical Trade Forecast
27
Table: Pharmaceutical Trade Data And Forecasts (Kuwait 2014-2020)
29
Table: Pharmaceutical Trade Data And Forecasts local currency (Kuwait 2014-2020)
29
Industry Risk Reward Index
30
Middle East and Africa Risk/Reward Index - Q3 2016
30
Kuwait Risk/Reward Index
38
Rewards
38
Risks
39
Regulatory Review
40
Intellectual Property Issues
42
Pricing Regime
43
Reimbursement Regime
45
Market Overview
50
Healthcare Sector
50
Clinical Trials
57
Epidemiology
57
Competitive Landscape
62
Research-Based Industry
62
Table: Multinational Company Activity
63
Pharmaceutical Distribution
64
Pharmaceutical Retail Sector
64
Company Profile
66
Advanced Technology Company
66
Bader Sultan & Bros
69
Kuwait-Saudi Pharmaceutical Industries (KSP)
72
Safwan Trading And Contracting Company
74
Demographic Forecast
76
Table: Population Headline Indicators (Kuwait 1990-2025)
77
Table: Key Population Ratios (Kuwait 1990-2025)
77
Table: Urban/Rural Population & Life Expectancy (Kuwait 1990-2025)
78
Table: Population By Age Group (Kuwait 1990-2025)
78
Table: Population By Age Group % (Kuwait 1990-2025)
79
Glossary
81
Methodology
83
Pharmaceutical Expenditure Forecast Model
83
Healthcare Expenditure Forecast Model
83
Notes On Methodology
84
Risk/Reward Index Methodology
85
Index Overview
86
Table: Pharmaceutical Risk/Reward Index Indicators
86
Indicator Weightings
87

The Kuwait Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Kuwait Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Kuwait pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Kuwait, to test other views - a key input for successful budgeting and strategic business planning in the Kuwaiti pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Kuwaiti pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Kuwait.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.